Quad Regimen for High-Risk Myeloma Produces High Rates of Durable MRD Negativity
Two-thirds of transplant-eligible patients met endpoint with isatuximab/KRd
Source: medpagetoday.com
Stay updated with breaking news from Katjac Weisel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two-thirds of transplant-eligible patients met endpoint with isatuximab/KRd